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ABSTRACT
Introduction and Aims: Gastrointestinal (GI)
complications such as gastric retention (GR) and
constipation are common after lung transplantation
(LT). Abdominal plain films (APFs) are a low-cost
diagnostic tool to detect impaired GI function. The goal
of our study was to assess the prevalence of GI
pathology seen on APF in lung transplant recipients
(LTRs) and to identify associated risk factors.
Methods: Retrospective analysis of consecutive LTRs
followed up between 2001 and 2013. Demographic,
radiographic and clinical data were assessed.
Results: 198 patients were included in the study, 166
thereof had more than 1 APF with a mean number of
5 APFs per patient. 163 patients had a detectable
radiographic pathology on APF. The proportion of LTR
with GR was highest among cystic fibrosis patients
(48.5%). Multivariate regression analysis showed a
significant association of diabetes with GR with a trend
for age and use of opiates as risk factors. Similarly,
female sex, advanced age and diabetes showed a trend
to be associated with lower GI tract complications.
Almost all patients had suffered from at least 1 episode
of lower GI dysmotility during a median follow-up of
5.7 years. No clear correlation between GI events and
the development of chronic lung allograft dysfunction
could be identified.
Conclusions: We found a statistically significant
association of diabetes with GR and a progressive
increase in the prevalence of GR over time after LT.
Lower GI complications affected >80% of LTR and
increased over time. Future studies correlating GI
transit with APF findings are needed.
INTRODUCTION
Lung transplantation (LT) is performed in
patients with non-malignant end-stage lung
diseases. Gastrointestinal (GI) complications
impact considerably on allograft and patient
survival and are frequently encountered in
this population.1–4 The underlying disease
leading to LT and pre-existing comorbidities
contribute to the development of GI compli-
cations after transplantation.
GI complications are frequent in lung trans-
plant recipients (LTRs) and are related to LT
surgery itself with possible vagal nerve
damage and altered diaphragmatic function,
immunosuppressive and other medications
used, which may affect intestinal motility and
content and consistency (ie, bacterial ﬂora
altered by prophylactic antibiotics or medica-
tion with laxative characteristics). Decreased
GI motility of the upper and lower GI tract is
frequently noted, despite the routine use of
prokinetic and laxative medication in LTR.
Among the most frequently observed compli-
cations are constipation, gastric retention
(GR), intestinal obstruction or perforation.5 6
Often abdominal complications initially
present with only minor or even absent symp-
toms and signs, so that laboratory investiga-
tions and imaging are the basis of diagnosis
and treatment.5 Abdominal radiography
usually as abdominal plain ﬁlm (APF) is a
simple, readily available diagnostic tool to
visualise consequences of delayed GI transit
due to GR, intestinal obstruction and consti-
pation. It may also detect free air in the
KEY MESSAGES
▸ Upper and Lower GI dysmotility is common
among lung transplant recipients.
▸ Abdominal plain films are a simple intial test to
assess the presence of dysmotility in these
patients.
▸ Gastric retention is common in patients after
lung transplantation and is associated with dia-
betes mellitus.
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abdominal cavity due to perforation. Diagnosis of these
conditions should trigger prompt further diagnostic
steps and guide treatment, since these complications
have signiﬁcant impact on necessary medical or surgical
treatment and patient survival.7 8
The objective of this study was to assess the prevalence
of radiological evidence of GR, intestinal and colonic
dysmotility detected on APF obtained for unclear
abdominal symptoms in LTRs. Furthermore, we aimed
to evaluate risk factors for GI complications as well as
the association of GI complications with the develop-
ment of chronic lung allograft dysfunction (CLAD), in
particular its most frequent form bronchiolitis obliterans
syndrome (BOS) and patient survival.
METHODS
We conducted a retrospective chart review and analyses of
the cohort of all LTRs at the University Hospital Zurich.
Patients who died within the ﬁrst month of transplantation
and patients who died before or in 2001 were excluded
from analysis. Furthermore, patients were excluded from
analysis if they refused retrospective data analysis.
LT is performed only at two centres in Switzerland,
Lausanne and Zurich. Patients receiving LT in Zurich
are treated according to our previously published proto-
cols, which include early postoperative and ongoing pro-
kinetic and laxative treatment as well as proton pump
inhibitors without prior motility testing and regular
24-hour pH studies as the prevalence of gastro-
oesophageal reﬂux and impaired GI motility is deemed to
be high after LT.5 BOS is regularly treated with macro-
lides, which has additional prokinetic effects. Additionally,
annual abdominal ultrasound scans are performed in
patients with CF before and after transplantation.
For a follow-up period from January 2001 to
November 2013, we documented and analysed compre-
hensive data on patient demographics, circumstances of
LT and medication as well as frequency and results of
abdominal radiographs taken irrespective of LT date.
Two observers (AN, HH) reviewed all APFs and veriﬁed
ﬁndings of the radiological report. In cases of discord-
ance between the radiology report and the viewer’s
assessment of APF, a third viewer was involved (MMS).
Coprostasis was documented when faecal loading in
either part of the colon without signs of obstruction was
present. Small bowel obstruction was deﬁned as the pres-
ence of dilated small bowel loops of more than 3 cm in
diameter in the centre of the abdomen. Large bowel
obstruction was documented when dilation of the colon
to more than 6 cm or more than 9 cm for the caecum
was seen on APF. Diffuse bowel obstruction was noted
when dilation of bowel loops could not be assigned to
the colon or small bowel. The presence of subdiaprag-
matic air was regarded as a sign of perforation.9–11
GR was deﬁned as an upper GI event.9 Lower GI
events were deﬁned as the presence of coprostasis, small
and/or large bowel obstruction, diffuse bowel
obstruction and perforation on APF. Evidence of compli-
cations like ileus and necessary surgery were documen-
ted from the electronic records.
Furthermore, lung function before, at the time of the
respective GI event and 6 months thereafter was evalu-
ated in order to assess the presence or progression of
CLAD/BOS in the time after the event.12
Statistical analyses were performed using STATA V.13.1
(StataCorp, College Station, Texas, USA). Data manage-
ment and descriptive statistics included presentation of
results in tables and graphs as appropriate. Risk factors
for the development of GP were calculated as
unadjusted univariate relative risks and as adjusted ORs
using multivariate logistic regression. Time-to-event ana-
lyses were performed using the Kaplan-Meier curves.
Permission for retrospective data analysis was obtained
from the Local Ethics Committee (KEK-ZH-Nr.2015-0162).
All patients had provided written informed consent for
research at the time of LT.
RESULTS
We included 198 patients who had received lung trans-
plants at our centre into the study cohort and followed
those between January 2001 and November 2013.
Demographics and characteristics of the study popula-
tion are presented in table 1. All 198 LTR contributed to
a combined total follow-up time of 1274 patient-years
with a median follow-up time of 5.7 years (range
74 days–12.9 years). Cystic ﬁbrosis was the most frequent
indication for LT accounting for 39.4% of the study
cohort. There were 963 APFs taken during follow-up for
the whole cohort, with a great variation in frequency as
shown in table 1.
Thirty-three patients (16.7%) had no APF at all and
33 (16.7%) had on average more than 2 APF per
patient-year of follow-up. During follow-up, 26 patients
(13.1%) died; of these, the cause of death was related to
a GI complication in only 2 patients with GI haemor-
rhage, 1 of which in combination with a bowel perfor-
ation. This mortality rate is not the mortality of the
whole cohort since patients who died within 30 days
after transplantation had been excluded (see the
Methods section). Frequencies of the clinical outcomes
of interest are summarised in table 2.
Gastric retention
We identiﬁed 35 patients (17.7%) with radiological evi-
dence of GR, of which almost half were patients suffer-
ing from CF. Fifteen patients showed signs of GR
without the presence of diabetes. Two of these suffered
from CF.
Twenty patients had diabetes and signs of GR.
Seventeen of these patients were insulin-dependent. The
three patients requiring no insulin were patients with CF.
Associations of various factors with incident GR were
explored in unadjusted univariate and in multivariate
analyses, and results are presented in table 3.
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We found a statistically signiﬁcant association of dia-
betes (CF and non-CF-related) with GR in the univariate
as well as in the adjusted multivariate analyses.
Furthermore, adjusted analysis showed non-signiﬁcant
trends towards an increased risk for the development of
GR in female patients (OR=1.8, 95% CI 0.8 to 4.0) and
those with opioid medication (OR=1.8, 95% CI 0.6 to
5.3), and there was a trend towards a protective effect of
macrolide antibiotics (OR=0.5, 95% CI 0.2 to 1.2).
Table 1 Demographics of the study cohort
Patient characteristics Number (%)*
All analysed lung transplant recipients 198 (100)
Sex
Female, n (%) 99 (50)
Male, n (%) 99 (50)
Indication for lung transplantation, n (%)
Cystic fibrosis (CF) 78 (39.4)
Chronic obstructive pulmonary disease (COPD) 52 (26.3)
Idiopathic pulmonary fibrosis (IPF) 32 (16.2)
Pulmonary arterial hypertension (PAH) 10 (5.1)
Other 26 (13.1)
Follow-up time†, median (range) 5.7 years (74 days–12.9 years)
Total follow-up time of cohort 1274 patient-years
Frequency of abdominal plain radiographs per patient, normalised for follow-up time. Categories by mean n APF per
patient-year
0 33 (16.7)
>0 to ≤0.5 50 (25.3)
>0.5 to ≤1 38 (19.2)
>1 to ≤2 44 (22.2)
>2 33 (16.7)
*Results given as number (%) unless indicated otherwise.
†Follow-up period: From January 2000 (or from date of lung transplantation if transplantation was performed after January 2001) to end of
November 2013.
Table 2 Observed outcomes during follow-up of the
study cohort
Patient characteristics n (%)*
All analysed lung transplant recipients 198 (100)
Deaths during follow-up 26 (13.1)
Patients with an event of GR 35 (17.7)
CF 17 (48,5)
With diabetes 12 (34)
COPD 7 (20)
With diabetes 1 (3)
IPF 6 (17)
Others 5 (14.5)
With diabetes 2 (6)
Patients with any lower gastrointestinal event† 165 (83.3)
Small bowel obstruction 13‡ (7.5)
Large bowel obstruction 14 (7.1)
Coprostasis 124 (62.6)
Diffuse bowel obstruction 13 (6.6)
Bowel perforation 1 (0.5)
Patients with up to 3 lower GI events 138 (69.7)
Patients with >3 repetitive lower GI events 79 (39.9)
Patients with an event of bronchiolitis
obliterans syndrome
52 (26.7)
*Results given as number (%) unless indicated otherwise.
†Patients may have more than one different lower GI event. The
sum of lower GI events therefore exceeds the number of patients
with any lower gastrointestinal event.
‡One patient with ileus as complication.
BOS, bronchiolitis obliterans syndrome; GI, gastrointestinal.
Table 3 Univariate and multivariate associations of
various factors with gastric retention
Factor
Relative risk
(unadjusted)
(95% CI)
OR (adjusted*)
(95% CI)
Female sex 1.5 (0.8 to 2.8) 1.8 (0.8 to 4.0)
Age >50 at LT 0.8 (0.4 to 1.5) 1.3 (0.5 to 3.3)
Diabetes 1.9 (1.0 to 3.4) 2.5 (1.1 to 6.1)
Domperidone 1.0 (0.3 to 2.8) 1.1 (0.3 to 4.2)
Laxatives 1.0 (0.5 to 2.2) 0.9 (0.4 to 2.5)
Opioids 1.4 (0.6 to 3.0) 1.8 (0.6 to 5.3)
Macrolide antibiotics 0.6 (0.3 to 1.1) 0.5 (0.2 to 1.2)
*Adjusted from multivariate logistic regression including all listed
factors. Possible associations with LT indication were explored but
revealed no significant effects.
LT, lung transplantation.
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Time to event analysis revealed a progressive risk of
developing GR after LT, with ∼30% of patients having
evidence of GR on APF 13 years after LT (ﬁgure 1).
Lower GI events
We identiﬁed 165 patients (83.3%) with lower GI events.
Unadjusted and adjusted associations of various factors
with lower GI events are presented in table 4.
Only one patient needed surgery for ileus and perfor-
ation. Further, there was an increased risk for lower GI
events associated with female sex, and laxative and
opioid use. Of note, due to the high proportion of
patients with lower GI events as the outcome of interest,
ORs from logistic regression are much higher than the
corresponding relative risks. Time to event analysis
demonstrated that a high proportion of patients already
had evidence of lower GI events early after transplant-
ation and that virtually all patients have evidence of
lower GI events when considering long-term follow-up
after transplantation (ﬁgure 2).
Bronchiolitis obliterans syndrome
Fifty-two patients (26.3%) had evidence of CLAD/BOS
based on pulmonary function testing 6 months after the
time of the lower GI event. Trends for mildly elevated
risks were observed for female sex (OR=1.6, 95% CI 0.8
to 3.1), patients who had received transplants for CF
(OR=1.5, 95% CI 0.5 to 4.8) and in patients with an
event of GR (OR=1.8, 95% CI 0.8 to 4.0). However,
there was no trend towards a higher adjusted risk in
patients with more than three lower GI events (OR=0.9,
95% CI 0.4 to 1.7).
DISCUSSION
This study assessed the prevalence and possible risk
factors for GI dysmotility seen on APF after LT over a
median follow-up time of 5.7 years. We found a statistic-
ally signiﬁcant association of diabetes with GR and a
prevalence of upper and lower GI complications as
documented on clinically indicated APF. Diabetes (type
II and CF-related) was identiﬁed as an important risk
factor for the development of GR in patients after LT.
Furthermore, the risk of developing GR increases with
time after transplantation. For lower GI complications
such as coprostasis, more than 80% of patients suffered
at least one episode after LT, and similar to GR, the
prevalence of lower GI events increases with time after
transplantation.
Figure 1 Time to event analysis
shows a progressive risk of
developing gastric retention (GR)
after lung transplant, with ∼30%
of patients developing evidence
of GR on abdominal plan films
during follow-up.
Table 4 Univariate and multivariate associations of
various factors with lower gastrointestinal events
Factor
Relative risk
(unadjusted)
(95% CI)
OR (adjusted*)
(95% CI)
Female sex 1.2 (1.1 to 1.4) 4.4 (1.7 to 11.6)
Age >50 years at LT 0.9 (0.8 to 1.1) 0.8 (0.2 to 2.8)
CF† 1.1 (0.9 to 1.2) 2.0 (0.4 to 10.5)
COPD† 1.0 (0.8 to 1.1) 1.1 (0.3 to 4.1)
IPF† 1.0 (0.8 to 1.2) 1.4 (0.3 to 5.9)
PAH† 1.1 (0.9 to 1.3) 3.9 (0.3 to 49.9)
Diabetes 1.0 (0.9 to 1.2) 0.9 (0.3 to 2.6)
Domperidone 1.1 (0.8 to 1.5) 1.8 (0.5 to 6.9)
Laxatives 1.2 (1.0 to 1.5) 2.6 (1.0 to 6.5)
Opioids 1.2 (1.1 to 1.3) 5.2 (0.6 to 41.9)
Macrolide antibiotics 1.0 (0.8 to 1.1) 0.7 (0.3 to 1.7)
*Adjusted from multivariate logistic regression including all listed
factors.
†Indications for lung transplantation (LT).
COPD, chronic obstructive pulmonary disease; IPF, idiopathic
pulmonary fibrosis; PAH, pulmonary arterial hypertension.
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The reported prevalence of upper and lower GI com-
plications after LT including malignancy is highly variable
in the literature depending on deﬁnition of complica-
tions, study focus and study population.8 13–15 A recent
retrospective study over 17 years reported 10.7% of
patients suffering from gastroparesis after LT using a clin-
ical deﬁnition.8 In our study population, 17.7% of
patients showed evidence of GR on APF reﬂecting the
larger proportion of patients with CF and diabetes in our
cohort. Whether the presence of CF-related diabetes and
diabetes mellitus in general have impact on survival after
transplantation is disputed in the literature.16 17
Multivariate regression showed a signiﬁcant correlation
between the presence of diabetes and GR. This patho-
physiologically plausible result suggests that diabetes is a
causal contributor to the development of GR in LTRs.
Vagal nerve damage is frequently mentioned as an
important reason for gastroparesis after LT surgery;3
however, the low prevalence of GR within the ﬁrst 30 days
after LT somewhat argues against this mechanism as the
predominant explanation for GR in most patients.
In addition, our results suggest that other causes than
diabetes such as medication related to LT play a role in
the development of GR and occurred despite standard
prokinetic treatment in all patients. Furthermore, GR
did not exclusively manifest in CF patients with diabetes,
but also in non-CF patients with and without diabetes,
suggesting a multifactorial mechanism for the develop-
ment of GR in LTRs. GR with possible gastro-
oesophageal reﬂux and aspiration poses a signiﬁcant
risk for the development of BOS.18 19 The prevalence of
GR increased progressively in our study population, with
about 30% of patients having had an episode of GR
during an observation time of up to 13 years after trans-
plantation. In our study population, we were able to
show that more than 25% of patients in our study
cohort with diabetes and GR fulﬁlled criteria of BOS
6 months after an upper GI event. Although this did not
reach statistical signiﬁcance, this ﬁnding emphasises the
importance of adequate medical diabetes management
pretransplantation and post-transplantation, and initiat-
ing prompt additional prokinetic treatment should GR
develop.
Based on published literature and our own clinical
observations, we assume that practically all LTRs have
gastro-oesophageal reﬂux to some extent, and therefore,
we implement physical, dietary and pharmacological
antireﬂux measures for all patients prophylactically.5 In
our cohort, none of the patients underwent antireﬂux
surgery. Future studies should investigate the utility of
routine gastric emptying and reﬂux testing in patients
after LT as a prognostic tool to tailor prevention and
treatment regarding the high percentage of GR in the
LT population.
Over 80% of patients in our study showed evidence of
impaired lower GI motility on APF during follow-up,
with coprostasis being the most common ﬁnding. Most
studies report an incidence of around 40% regarding
colitis and diverticulitis after LT.8 The high proportion
of patients with lower GI dysmotility detected in our
study can be attributed to mostly minor medical compli-
cations like coprostasis not being assessed in most other
studies and the low threshold for diagnostic tests in the
setting of abdominal symptoms at our centre. In our
practice, laxative therapy is intensiﬁed in patients after
LT when coprostasis is seen on APF to minimise the risk
of abdominal complications such as vomiting, diverticu-
litis or perforation.5
Furthermore, our results demonstrate that virtually all
patients suffer from impaired lower GI motility after LT
at some point in time in spite of standard laxative
therapy, and that the prevalence increases with time
Figure 2 A high proportion of
patients’ experiences lower
gastrointestinal events shortly
after transplantation and that
virtually all patients accumulate
evidence of a lower
gastrointestinal event during
follow-up time after
transplantation.
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after transplantation, suggesting a late-onset aetiology
such as autonomic neuropathy or possible vascular
changes that may develop many years after LT.
Opioid medication should be used with caution in
patients after LT, mainly due to its slowing effect on GI
motility. Our data show that patients who received
opioid medication had a trend towards a higher risk of
developing upper or lower GI complications like GR or
colonic motility impairment. Possibly due to the sparse
administration of opioids at our centre, this trend failed
to reach statistical signiﬁcance and only one patient
required surgery due to ileus and bowel perforation.6
Our study has several limitations. Data were collected
retrospectively, which makes the data vulnerable to bias
related to staff turnover and evolution of medical prac-
tice and technology over time. APFs were performed at
the discretion of the treating physician, which might
contribute to a selection bias. However, the threshold
for performing an APF in LT patients presenting with
abdominal symptoms has been consistently low at our
centre over time. Our data comprise a large number of
LTR who were treated according to standardised proce-
dures and with objective measurements, so that data of
prescribed medication, lung function and treatment
modiﬁcations are of high quality. A further limitation is
the lack of veriﬁcation of gastroparesis by gastric empty-
ing studies such as 13C breath tests, which however also
have inherent limitations. The sensitivity and speciﬁcity
of APF for GR could therefore not be assessed. In add-
ition, even though all radiographs were evaluated by our
study team with discussion of ambiguous cases, a formal
analysis for interobserver agreement was not performed.
Furthermore, clinical decision-making is a complex
process and our chart review could not unequivocally
identify changes in management caused by APF.
Although no direct comparison of APF and CT scan
results was made, the low incidence of major GI compli-
cations as assessed by the need for surgical intervention
in our cohort when compared with other cohorts may
suggest that the strategy of using APF as a primary diag-
nostic tool besides obtaining routine laboratory investi-
gations might be considered useful and help justify its
utility in clinical practice.6 Cost, radiation exposure, time
and availability are other factors that favour our
approach using an APF as an initial diagnostic tool in LT
patients with unspeciﬁc abdominal symptoms.
Lower and upper GI complications are common and
have been described previously after LT. APF can easily
and swiftly be obtained and can provide useful informa-
tion: APF consistent with coprostasis or GR as an explan-
ation for patient symptoms would prompt intensiﬁed
medical treatment or aggressive diagnostics such as CT
scan in the case of the presence of bowel obstruction or
signs of perforation. Follow-up APF also provides an
objective measure for resolution of coporostasis and GR
in the case of ambiguous clinical ﬁndings.
The results of our study have important implications for
clinical practice: Underlying medical conditions like
diabetes are a clinically important risk for the develop-
ment of GR and opioid medication should be avoided
whenever possible after LT. A high level of suspicion is war-
ranted concerning the development of coprostasis despite
laxative treatment. AFP provides quick information if GI
dysmotility is present and can stratify the need for further
diagnostics such as computer tomography and can guide
intensiﬁed prokinetic and laxative treatment. Further
studies should evaluate whether a ﬁrst event of gastric/
intestinal dysmotility after LT should trigger further motil-
ity testing like gastric emptying studies, pH metry for
reﬂux testing and intestinal transit studies, whether these
tests identify risk groups for GI dysmotility and if the
results have an impact on treatment, outcome and survival.
While management of LT patients should ideally be
carried out at specialised centres, we recommend to plan
treatment in a multidisciplinary team, which should
involve gastroenterologists, in particular motility specialists
when recurrent episodes of GI dysmotility are noted.
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